US-based biotechnology company Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma ...

【导读】PBRM1失活突变与免疫检查点抑制剂治疗后肾细胞癌（ccRCC）的临床获益相关。然而，靶向PBRM1是否有潜力增强免疫治疗效果尚不清楚。12月10日，西安交通大学李磊教授研究团队在期刊《Advanced ...

Neoadjuvant therapy for high-risk renal cell carcinoma (RCC) may offer a survival advantage over adjuvant therapy, according to data presented at the 2024 annual meeting of the Society of Urologic ...

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Adicet Bio ( (ACET) ) has issued an update.

This paper presents the important discovery that lipid metabolic imbalance caused by Snail, an EMT-related transcription factor, contributes to the acquisition of chemoresistance in cancer cells.

Brandy Verdin, 49, lives with her husband in Gray, Louisiana. She was diagnosed with Stage IV renal cell carcinoma in May 2023.

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.